Evidence map›Paper›PMID 34109466›Full record

ArticleRheumatology international2021

Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly.

Emire Seyahi, Guldaran Bakhdiyarli, Mert Oztas, Mert Ahmet Kuskucu, Yesim Tok, Necdet Sut, Guzin Ozcifci, Ali Ozcaglayan, Ilker Inanc Balkan, Nese Saltoglu and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 13 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 13 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Pooled it
  10. Pooled it
  11. Guideline
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Observational
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Emire SeyahiDivision of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, 81310, Turkey. eseyahi@yahoo.com.ORCID http://orcid.org/0000-0003-4965-2918
Guldaran BakhdiyarliDepartment of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-2629-3345
Mert OztasDivision of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, 81310, Turkey.ORCID http://orcid.org/0000-0002-4077-1374
Mert Ahmet KuskucuDepartment of Microbiology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-8735-5725
Yesim TokDepartment of Microbiology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-4970-9216
Necdet SutDepartment of Biostatistics and Medical Informatics, Trakya University Medical Faculty, Edirne, Turkey.ORCID http://orcid.org/0000-0001-6678-482X
Guzin OzcifciCerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-4774-9284
Ali OzcaglayanCerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-1810-5495
Ilker Inanc BalkanDepartment of Infectious Diseases and Clinical Microbiology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-8977-5931
Nese SaltogluDepartment of Infectious Diseases and Clinical Microbiology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-4239-9585
Fehmi TabakDepartment of Infectious Diseases and Clinical Microbiology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-8632-2825
Vedat HamuryudanDivision of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, 81310, Turkey.ORCID http://orcid.org/0000-0001-6625-1652
Istanbul University-Cerrahpaşa · TRTrakya University · TR

Funding

Turkish Society of Rheumatology 26.03.2021/5
6 · The paper itself

Abstract

objectiveTo assess antibody response to inactivated COVID-19 vaccine in patients with immune-mediated diseases (IMD) among hospital workers and people aged 65 and older.

methodsIn this cross-sectional study, we studied 82 hospital workers with IMD (mean age: 42.2 ± 10.0 years) and 300 (mean age: 41.7 ± 9.9 years) controls. Among + 65 aged population, we studied 22 (mean age: 71.4 ± 4.5 years) patients and 47 controls (mean age: 70.9 ± 4.8 years). All study subjects had a negative history for COVID-19. Sera were obtained after at least 21 days following the second vaccination. Anti-spike IgG antibody titers were measured quantitatively using a commercially available immunoassay method.

resultsPatients with IMD were significantly less likely to have detectable antibodies than healthy controls both among the hospital workers (92.7% vs 99.7%, p < 0.001) and elderly population (77.3% vs 97.9%, p = 0.011). Among patients with IMD, those using immunosuppressive or immune-modulating drugs (64/75, 85.3%) were significantly less likely to have detectable antibodies compared to those off treatment (29/29, 100%) (p = 0.029). Additionally, a negative association between age and the antibody titer categories among patients (r = - 0.352; p < 0.001) and controls (r = - 0.258; p < 0.001) were demonstrated.

conclusionsAmong hospital workers, the vast majority of patients with IMD and immunocompetent controls developed a significant humoral response following the administration of the second dose of inactivated COVID-19 vaccine. This was also true for the elderly population, albeit with lower antibody titers. Immunosuppressive use, particularly rituximab significantly reduced antibody titers. Antibody titers were significantly lower among those aged ≥ 60 years both in patient and control populations. Whether these individuals should get a booster dose warrants further studies.

Indexed as

Immunity, HumoralImmunogenicity, VaccineMass VaccinationPersonnel, HospitalAdultAgedAge FactorsAntibodies, ViralBiomarkersCase-Control StudiesCOVID-19 VaccinesCross-Sectional StudiesFemaleHumansImmune System DiseasesImmunization ScheduleAntibodies, ViralBiomarkersCOVID-19 VaccinesImmunoglobulin GVaccines, InactivatedAntibody to S1 spike proteinCoronaVacCOVID-19ElderlyHospital workersInflammatory diseasesSeroprevalenceVaccination

Identifiers

PMID34109466
PMCPMC8188953
OpenAlexW3172019122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.